. 2019 May 16;12:1537–1551. doi: 10.2147/JPR.S190162

Table 1.

Effects of tapentadol on neuropathic pain

Author	Condition	Study features				Tapentadol mean daily dose (mg)	Pain		Neuropathic pain
Patient number	Duration (months)	Type	Comparator	NRS/VAS decrease	Responders (%)	DN₄/NPSI/PDQ decrease	Responders (%)
Musculoskeletal pain conditions
Billeci⁸⁸	CNP	44	3	PO		204.5±102.8	5.1	68^B	DN₄, 2.2^B	47^dB
Baron⁸⁵	LBP	130	3	RCT	Oxycodone	378.8±129.6	3.7		PDQ, 10.8
Baron⁸³	LBP	59 154 159	3	PO DB DB	Pregabalin	300 500 300	5.2 4. 4.2		PDQ, 12.3^B PDQ, 10.3^B PDQ, 11.0^B
Passavanti⁸⁴	LBP	55	6	R PO	Tapentadol-PEA	158.0±8.50 121.7±6.20	−1.8^A	68^cA	DN₄, 1.8^A	28^cA
Tedeschi⁶¹	PAD	25	3	PO		186.4±56.0	5.1^B	80^a	DN₄, 2.8^B	78^d
Ueberall⁸⁶	LBP	133	3	R	Oxycodone	298.5±71.2	31.2^A −3.8^B	84^g −1.7	PDQ₇, 5	42^a
Cancer pain conditions
Sugiyama¹⁰³	SC	30	2,1	R		100	3
Brunetti⁹⁴	HC	36	1	PO		243.5±105.6	7		DN₄, 3.4	75^d
Coluzzi⁹³	MM	25	3	PO		213.6±94.1	4,7		DN₄, 4.3	100^d
Neurological pain conditions
Galiè⁶⁵	CIPN	31	3	PO		200	3.4^B	86^a	DN₄, 2.2^B	78^b
Vinik⁵⁹	DPN	318	3	RCT	Placebo	100–250	0.95^A	40^A^a	NPSI, 8.84^A
Niesters⁴³	DPN	25	1	RCT	Placebo	433±31	0.8^A
Schwartz⁶⁰	DPN	196	3	RCT	Placebo	200–500	1.3^A	39^a
Freo¹⁰²	PD	21	6	R		206.3±102.7	2.5^B	48^a	PDQ, 6.3^B	100^f

Notes: Responders: ^aVAS/NRS ≥50% reduction; ^bDN₄>30% reduction; ^cVAS and/or DN₄ 2 point reduction; ^dDN₄<4; ^ePDQ7 reduction to <18; ^fPD reduction to ≤18; ^glow back pain intensity index. Statistics: ^Aintergroup comparison, significantly different from placebo or oxycodone; ^Bintragroup comparison, significantly different from baseline.

Abbreviations: CIPN, chemotherapy induced peripheral neuropathy; DN₄, douleur neuropathique en 4 questions; DPN, diabetic peripheral neuropathy; HC, hematholocical cancer; LBP, low back pain; multiple myeloma; NPSI, Neuropathic Pain Symptom Inventory; NRS/VAS, 0–10 Numerical Rating Scale/0–10 Visual Analogue Scale; NP, neuropathic pain; PDQ, painDetect questionnaire; PDQ7, seven-item painDetect; PD, Parkinson’ disease; PEA, palmytoilethanoamine; PHN, postherpetic neuralgia; PO, prospective observational; R, retrospective; RCT, randomized-controlled trial; SC: solid cancers.